Benchmark upgraded Repligen rating to buy, while Jefferies Financial Group reaffirmed a hold rating on the company.
1 report, 1 independent
Updated Aug 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Benchmark upgraded Repligen rating to buy, while Jefferies Financial Group reaffirmed a hold rating on the company.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Repligen
bioTech Company
Nothing else this week.
-
Benchmark
venture capital firm
-
Jefferies Financial Group
American financial services company
Related events
- Jefferies Financial Group upgraded Reckitt's stock rating to 'buy' on October 11, 2026.
- Jefferies reiterated a hold rating while Citigroup increased its target price and gave a neutral rating for QuidelOrtho Corporation.
- Jefferies Financial Group restated a 'buy' rating for Living REIT plc on October 15, 2026.
- Jefferies Financial Group restated a buy rating on Wise shares.
- Jefferies Financial Group cut the stock rating for Carlsberg Group to 'hold' on October 13, 2026.